Clinical trial
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
NCT00165490 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165490 |
|---|---|
| Title | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer |
| Official title | Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus |
| Intervention type | Device, Drug, Procedure |
| Interventions | Cetuximab, Cisplatin, Irinotecan, Radiation therapy, Surgery |
| Enrollment | 19 |
| Start date | Aug 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2014 |
| First posted | Sep 14, 2005 |
| Last update posted | Nov 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: